Filing Flows › NewAmsterdam Pharma Co N.V. (NAMS) › Q2 2025
NewAmsterdam Pharma Co N.V. (NAMS) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 6, 2025
NewAmsterdam Pharma Co N.V. (NAMS) reported revenue of $19.1M for the second quarter 2025 (Q2 2025), +740% from a year earlier and +543% from the quarter before. Operating margin was -186.1%, net loss $17.4M (90.7% of revenue).
NewAmsterdam Pharma Co N.V., Q2 2025: revenue $19.1M (+740% year over year), operating margin -186.1%, net loss $17.4M, operating cash flow −$37.7M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $19.1M | +543% | +740% |
| Operating profit | −$35.6M | — | — |
| Net earnings | −$17.4M | — | — |
| Operating cash flow | −$37.7M | — | — |
What changed
Revenue was $19.1M in Q2 2025, up 740% year over year and up 543% from the previous quarter.
Operating costs exceeded revenue by $35.6M, an operating margin of -186.1%. Total costs fell 0% while revenue rose 740%. The fastest-growing cost line was SG&A (+65%). The quarter ended with a net loss of $17.4M, narrower than the previous quarter's $39.5M loss. Non-operating items added $18.3M, -105% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$37.7M. Non-cash charges added back $45K of depreciation and amortization and $15.2M of share-based compensation. Working capital and other items used $35.5M. Capital expenditures of $88K exceeded it, leaving free cash flow of −$37.8M.
Questions
What was NewAmsterdam Pharma Co N.V.'s revenue in the second quarter 2025?
NewAmsterdam Pharma Co N.V.
Was NewAmsterdam Pharma Co N.V. profitable in the second quarter 2025?
Operating loss was $35.6M (-186.1% of revenue) and net loss $17.4M.